Sodium valproate in the treatment of levodopa-induced dyskinesia.

Price, Paul A.; Parkes, J. D.; Marsden, C. D.

doi:10.1136/jnnp.41.8.702

Cited by 49 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All other ADRs like dyskinesia and other psychotic reactions in parkinson disease were probably preventable due to poor predictability of ADRs and poorly understood mechanisms to explain their cause. [25][26][27] Majority of the reported ADRs were of mild severity and hence, there would be no strong indication to change or withhold the drug. This was similar to mild to moderate severity ADRs reported with trihexyphenidyl.…”

Section: Discussionmentioning

confidence: 99%

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

Thaha

Gangadhar

Iype

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Parkinson disease (PD) generally requires therapy for prolonged periods often with multiple drugs; drug-related adverse effects often add to the existing morbidity. Although, such ADRs are common, comprehensive information about their incidence, severity, and ultimate health effects are not available. The objective of the study was to analyze the pattern of occurrence of Adverse Drug Reactions (ADRs) in patients receiving anti-parkinson agents (APA) in a tertiary care hospital. We also aimed to assess the causality, severity and preventability of these ADRs.Methods: This prospective, observational study with 6 month follow up was conducted among consecutive PD patients receiving anti parkinson agents attending the Movement disorder clinic of Neurology department between April 1st 2011 and September 30th 2012. Tools used were ADR Reporting form of National Pharmacovigilance centre, WHO causality scale, Hartwig and Siegel scale to assess severity and Schumock and Thornton scale to assess preventability of ADRs. Descriptive statistics was used and the values were expressed in numbers and percentages.Results: ADRs were experienced in 87 patients (82.1%) out of 106 patients and most of these patients were on combination therapy (66%). No gender difference in distribution of ADRs was observed. The most common reactions were sedation, dizziness, dry mouth and fatigue. The drug usage was in the order of pramipexole (58.4%), levodopa+carbidopa (55.7%), trihexyphenidyl (28.3%), entacapone (5.7%) and amantadine (7.5%). Majority of the ADRs were mild level 1 (71.1%). ADR was maximum with entacapone. Majority of ADRs belonged to the causality possible ADR category. All the ADRs came under the definitely or probably preventable category.Conclusions: ADRs with antiparkinsonian drugs is common but mild and preventable.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

Thaha

Gangadhar

Iype

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…In contrast to histone H 3 , there is evidence of marked histone H 4 deacetylation in the striatum of both dyskinetic MPTP-lesioned NHPs and dyskinetic 6-OHDA-lesioned mice killed at peak LID expression (Nicholas et al, 2008). Accordingly, in the MPTP-lesioned NHP, inhibiting histone deacetylation with the histone deacetylase (HDAC) inhibitor RGFP109 effectively alleviated LID (Johnston et al, 2010a) and sodium valproate, which acts as a nonselective HDAC inhibitor (Rosenberg, 2007), reduced dyskinesia severity in a small clinical study (Price et al, 1978). Although the genes affected by these changes in chromatin structure remain to be identified, the finding of histone deacetylation in LID adds to the complexity of the phenomenon.…”

Section: A Transcription Factorsmentioning

confidence: 99%

The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

Huot

Johnston²,

Koprich³

et al. 2013

Pharmacol Rev

288

230

View full text Add to dashboard Cite

“…Regarding Parkinson's disease (PD), relatively dated clinical data reported no amelioration of patients treated with VPA (Price et al 1978;Nutt et al 1979). However, recent in vitro studies have raised novel interest on the possible use of VPA in PD-like neurodegeneration.…”

Section: Introductionmentioning

confidence: 99%

Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

et al. 2009

View full text Add to dashboard Cite

Valproic acid (VPA), an established antiepileptic and antimanic drug, has recently emerged as a promising neuroprotective agent. Among its many cellular targets, VPA has been recently demonstrated to be an effective inhibitor of histone deacetylases. Accordingly, we have adopted a schedule of dietary administration (2% VPA added to the chow) that results in a significant inhibition of histone deacetylase activity and in an increase of histone H3 acetylation in brain tissues of 4 weeks-treated rats. We have tested this schedule of VPA treatment in an animal model of Parkinson's disease (PD), in which degeneration of nigro-striatal dopaminergic neurons is obtained through sub-chronic administration of the mitochondrial toxin, rotenone, via osmotic mini pumps implanted to rats. The decrease of the dopaminergic marker tyrosine hydroxylase in substantia nigra and striatum caused by 7 days toxin administration was prevented in VPA-fed rats. VPA treatment also significantly counteracted the death of nigral neurons and the 50% drop of striatal dopamine levels caused by rotenone administration. The PD-marker protein alpha-synuclein decreased, in its native form, in substantia nigra and striatum of rotenone-treated rats, while monoubiquitinated alpha-synuclein increased in the same regions. VPA treatment counteracted both these alpha-synuclein alterations. Furthermore, monoubiquitinated alpha-synuclein increased its localization in nuclei isolated from substantia nigra of rotenone-treated rats, an effect also prevented by VPA treatment. Nuclear localization of alpha-synuclein has been recently described in some models of PD and its neurodegenerative effect has been ascribed to histone acetylation inhibition. Thus, the ability of VPA to increase histone acetylation is a novel candidate mechanism for its neuroprotective action.

show abstract

Sodium valproate in the treatment of levodopa-induced dyskinesia.

Cited by 49 publications

References 17 publications

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

Contact Info

Product

Resources

About